<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05030701</url>
  </required_header>
  <id_info>
    <org_study_id>PI2021_843_0072</org_study_id>
    <nct_id>NCT05030701</nct_id>
  </id_info>
  <brief_title>Toxicity of Treatments for Non-tuberculous Mycobacterial Infections in Cancer Patients or Not</brief_title>
  <acronym>MYCATRES</acronym>
  <official_title>Toxicity of Treatments for Non-tuberculous Mycobacterial Infections in Cancer Patients or Not</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-tuberculous mycobacteria (NTM) are increasingly common and have a poor prognosis: 5-year&#xD;
      mortality can reach 40 to 50%, depending on the type of mycobacteria and the immune system of&#xD;
      the host involved. Cancer patients are at higher risk of infectious morbidity and mortality,&#xD;
      which may be due to disease-related immune dysfunction, immunosuppressive effects of&#xD;
      chemotherapy, or long-term placement of a vascular catheter. However, data on the treatment&#xD;
      of NTM species that cause infections and the disease characteristics of these pathogens in&#xD;
      cancer patients are limited despite the growing cancer population worldwide. Recently, M.&#xD;
      avium infections have been described in patients suffering from cancers (hematological or&#xD;
      not), in particular in patients receiving checkpoint inhibitors. Although the proportion of&#xD;
      M. avium pneumonia in retrospective series is low (0.8-2%), it has been shown that this&#xD;
      population is younger, suffers less from sub-pulmonary pathology. (indicating&#xD;
      immunosuppression in these patients) but are therefore treated less than non-cancerous&#xD;
      subjects.&#xD;
&#xD;
      This retrospective study in CHU Amiens is searching on the number of side effects of NTM&#xD;
      treatment in two groups (cancerous and no cancerous) to assess the cause of the decrease of&#xD;
      NTM treatment in cancerous patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>variation of side effects number of non-tuberculous mycobacteria treatment between cancerous and non cancerous patient groups.</measure>
    <time_frame>3 months</time_frame>
    <description>The main objective of this study is to determine the number of side effects of the treatment of non-tuberculous mycobacteria in patients with this infection with or without cancer at the CHU Picardie Amiens.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Mycobacterium</condition>
  <condition>Cancer</condition>
  <condition>Treatment Side Effects</condition>
  <arm_group>
    <arm_group_label>cancerous patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>non cancerous patients</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients infected with Nontuberculous mycobacteria, collected from CHU Amiens 2015 to 2020,&#xD;
        extracted from the medical information service by the RUM (medical unit summary) with a&#xD;
        diagnostic code ICD-10 which is the International Classification of diseases, commonly&#xD;
        known as the international statistical classification of diseases and related health&#xD;
        problems and Chapters A31.0, A31.8, A31.9.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age equal or more than 18 years18&#xD;
&#xD;
          -  Patients diagnosed by an infection with non-tuberculous mycobacteria according to ATS&#xD;
             guidelines.&#xD;
&#xD;
          -  Patients received the NTM treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age less than 18 years&#xD;
&#xD;
          -  Patients diagnosed by NTM without treatment.&#xD;
&#xD;
          -  Patients with a positive sample of NTM but without infection.&#xD;
&#xD;
          -  Exclusion of other disorders such as tuberculous.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean Philippe LANOIX, MD</last_name>
    <phone>03 22 66 83 73</phone>
    <email>Lanoix.jean-philippe@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <state>Picardie</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Philippe LANOIX, Dr</last_name>
      <phone>03 22 66 83 73</phone>
      <email>lanoix.jean-philippe@chu-amiens.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mycobacterium</keyword>
  <keyword>cancer</keyword>
  <keyword>Treatment Side Effects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycobacterium Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

